Bolt Biotherapeutics Inc (BOLT)
0.6203
+0.04
(+6.31%)
USD |
NASDAQ |
Sep 27, 16:00
0.6588
+0.04
(+6.21%)
After-Hours: 20:00
Bolt Biotherapeutics SG&A Expense (Annual): 22.53M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 22.53M |
December 31, 2022 | 22.93M |
December 31, 2021 | 18.39M |
Date | Value |
---|---|
December 31, 2020 | 9.056M |
December 31, 2019 | 5.182M |
December 31, 2018 | 2.209M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
5.182M
Minimum
2019
22.93M
Maximum
2022
15.62M
Average
18.39M
Median
2021
SG&A Expense (Annual) Benchmarks
SeaStar Medical Holding Corp | 8.237M |
CVS Health Corp | -- |
NovaBay Pharmaceuticals Inc | 12.83M |
Palatin Technologies Inc | 15.29M |
iBio Inc | 11.67M |